April 30, 2014 --The first time Dana gave marijuana to her 13-year-old son, it was a mother’s act of desperation.
Edward has absence seizures, also known as petit mal seizures. At least a dozen times a day, he blanks out for about 20 seconds. The seizures affect his school work and memory. His mother lives in constant fear that he’ll fall down a flight of stairs or step into traffic while he’s having one.
And like one-third of all people with epilepsy, medication does little to control his seizures. When Dana heard news reports about a strain of marijuana grown in her home state of Colorado that helped reduce seizures in some children, she was intrigued. For close to 4 months, Edward took medical marijuana pills. They were low in THC, the ingredient in marijuana that affects mood, but high in cannabidiol (CBDs), a non-mood-altering ingredient in pot. Supporters of CBD marijuana say it shows promise against epilepsy, but far from everyone agrees.
“We saw absolutely nothing, nothing positive or negative, just as if we were giving him a vitamin,” says Dana, of Golden, CO, who asked that her last name not be used. Both medical and recreational marijuana are legal in Colorado. “It was definitely a letdown that we weren’t seeing the effects that other people said they had seen early on. We had high hopes and nothing was happening.”
At a time when hundreds of families have moved or are planning to move to Colorado in search of this treatment, such stories are a sobering reminder of the difficulty of controlling drug-resistant epilepsy.
Estimates of the effectiveness of CBDs vary widely. While supporters in Colorado say 3 out of 4 patients have seen some benefits, some epilepsy specialists believe just 1 in 4 patients sees any improvement. Neither estimate is based on hard evidence. There has been little scientific testing of CBDs. Understanding of their impact is further hampered by reluctance among patients’ families to reveal that they've tried it and among most doctors to recommend it.